A market forecast from IndexBox projects the global non-GMO collagen peptides market growing at a 7.2% compound annual rate from 2026 to 2035, reaching a market index of 185 by 2035 against a 2025 baseline of 100. IndexBox notes that indexed curves are used here because full absolute volumes are not publicly disclosed, which is worth holding onto before anyone quotes a dollar figure.

Collagen peptides are hydrolyzed collagen protein, sourced from bovine, marine or other animal material, and the report defines this category specifically as product carrying a non-GMO claim and positioned for general wellness, beauty-from-within and joint health. The interesting part is what has happened to that claim: IndexBox describes non-GMO certification as having moved from a niche differentiator to a foundational requirement for credible participation in developed markets.

Where the volume sits

Dietary supplements remain the largest end use, at an estimated 45% of global demand in 2025, with a projected 7.5% CAGR through 2035. Functional food and beverage is second at roughly 25%, and IndexBox expects it to grow faster than any other large segment at 8.2%, which is the number a category manager should actually be watching.

Sports nutrition takes about 15% of demand with a projected 6.8% CAGR, and cosmeceuticals and beauty products hold roughly 10% at a projected 9.1%, the steepest rate in the set but from a smaller base. Pharmaceuticals and clinical nutrition sit at around 5%, growing a projected 5.5%.

A claim that no longer differentiates

When a label claim becomes table stakes, it stops being a reason to charge more, and the report's own framing concedes the pricing power has moved elsewhere. IndexBox describes a steep price ladder anchored by mass-market private label at the value end and clinically positioned products at the super-premium end, with brand control fragmented between incumbent wellness brands, digitally native brands and private-label programs.

Route to market is hybridizing, with subscription DTC and e-commerce taking a growing share of volume and compressing traditional distribution margins. Traceability and supply chain integrity are described as becoming brand assets in themselves, pushing companies toward vertical integration or source-verified supplier partnerships.

What the 7.2% assumes

The baseline scenario rests on continued premiumization in developed markets and rising adoption in emerging ones as local manufacturing scales, and it explicitly assumes regulatory harmonization does not arrive. IndexBox lists raw material price volatility, supply chain disruption and competition from synthetic alternatives as the key risks to that trajectory.